tbuckley/cabot-search huggingface dataset:
腰椎脊髄損傷動物モデルにおける細胞療法を用いたペプチド修飾ジェランガムヒドロゲルの組合せ【Powered by NICT】
Authors: D Gomes Eduardo, S Mendes Sofia, Leite-Almeida Hugo, M Gimble Jeffrey, Y Tam Roger, S Shoichet Molly, Sousa Nuno, A Silva Nuno, J Salgado Antonio
Journal: Biomaterials (2016)
The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
Authors: Nickhill Bhakta, Qi Liu, Kirsten K Ness, Malek Baassiri, Hesham Eissa, Frederick Yeo, Wassim Chemaitilly, Matthew J Ehrhardt, Johnnie Bass, Michael W Bishop, Kyla Shelton, Lu Lu, Sujuan Huang, Zhenghong Li, Eric Caron, Jennifer Lanctot, Carrie Howell, Timothy Folse, Vijaya Joshi, Daniel M Green, Daniel A Mulrooney, Gregory T Armstrong, Kevin R Krull, Tara M Brinkman, Raja B Khan, Deo K Srivastava, Melissa M Hudson, Yutaka Yasui, Leslie L Robison
Journal: The Lancet (2017)
Biomimicry, Biofabrication, and Biohybrid Systems: The Emergence and Evolution of Biological Design
Authors: Ritu Raman, Rashid Bashir
Journal: Advanced Healthcare Materials (2017)

Abstract The discipline of biological design has a relatively short history, but has undergone very rapid expansion and development over that time. This Progress Report outlines the evolution of this field from biomimicry to biofabrication to biohybrid systems’ design, showcasing how each subfield incorporates bioinspired dynamic adaptation into engineered systems. Ethical implications of biological design are discussed, with an emphasis on establishing responsible practices for engineering non‐natural or hypernatural functional behaviors in biohybrid systems. This report concludes with recommendations for implementing biological design into educational curricula, ensuring effective and responsible practices for the next generation of engineers and scientists.
Intensive Chemotherapy with DA-Edoch Followed By Allogeneic Hematopoietic Stem Cell Transplantation Improved the Outcome in HTLV-1 Associated Adult T Cell Leukemia (ATL)
Authors: Jianda Hu, Ting Yang, Zhengjun Wu, Jinghua Ren, Xiaoyun Zheng, Tingbo Liu, Zhizhe Chen
Journal: Blood (2016)
Two-year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB): SIOPEL 6.
Authors: Penelope Rachel Brock, Margaret Childs, Kaukab Rajput, Rudolf Maibach, Derek Roebuck, Michael James Sullivan, Veronique Laithier, Milind Ronghe, Patrizia dall'Igna, Eiso Hiyama, Bénédicte Brichard, Jane Skeen, Maria Elena Mateos, Monique Fabre, Giorgio Perilongo, Piotr Czauderna, Bruce Morland, Edward A. Neuwelt
Journal: Journal of Clinical Oncology (2016)

10514 Background: SIOPEL 6 is a phase III randomized trial in SR-HB which is defined as tumor extension limited to PRETEXT I, II or III, no portal or hepatic vein involvement, no intra-abdominal extrahepatic disease, AFP >100ng/ml and no metastases. A serious permanent side effect of cisplatin (Cis) therapy is bilateral high-frequency hearing loss which is particularly debilitating when it occurs at a young age. Sodium thiosulfate (STS) has been shown to dramatically reduce hearing loss in children treated with cisplatin containing chemotherapy without tumor protection in localized disease: COG ACCL0431: 2014 ASCO Annual Meeting Abstract No: 10017. Methods: Newly diagnosed patients with SR-HB were randomized to Cis or Cis+STS for 4 preop and 2 postop courses. Cis 80mg/m2 was administered i.v. over 6 hrs. STS was administered i.v. exactly 6 hrs. after stop of Cis over 15 minutes at 20g/m2. Tumor response was assessed after 2 and 4 cycles preop with serum AFP and liver imaging. In case of progressive disease (PD) STS was to be stopped and chemotherapy changed to combination therapy with Cis and Doxorubicin 60mg/m2. The primary endpoint of the trial is centrally reviewed absolute hearing threshold, at the age of ≥3.5 yrs, by pure tone audiometry. Secondary endpoints are event free (EFS) and overall survival (OS). Results: 109 patients (52 Cis and 57 Cis+STS) were recruited at trial closure in December 2014. The combination of Cis+STS was generally well tolerated. The median follow up is 32.2 months and provisional 2 yr EFS is Cis 86.3% and Cis+STS 89.0%; 2 yr OS is Cis 91.4% and Cis+STS 97.7%. Treatment failure defined as PD at 4 cycles was equivalent in both arms (3 Cis; 3 Cis+STS). As of February 2016, 5 patients had died (4 Cis; 1 Cis+STS) 1 had relapsed (Cis+STS) and 1 was still in PR (Cis+STS). Interim results of centrally reviewed and Brock graded audiograms for 68 pts at age ≥3.5yrs are encouraging. Definitive results will become available end 2017. Conclusions: This randomized phase III trial in standard risk hepatoblastoma of cisplatin alone vs cisplatin plus the otoprotectant STS shows comparable 2 year EFS and OS with no evidence of tumor protection. Clinical trial information: NCT00652132.
Accuracy of Cardiovascular Risk Prediction Varies by Neighborhood Socioeconomic Position
Authors: Jarrod E. Dalton, Adam T. Perzynski, David A. Zidar, Michael B. Rothberg, Claudia J. Coulton, Alex T. Milinovich, Douglas Einstadter, James K. Karichu, Neal V. Dawson
Journal: Annals of Internal Medicine (2017)

Inequality in health outcomes in relation to Americans' socioeconomic position is rising.First, to evaluate the spatial relationship between neighborhood disadvantage and major atherosclerotic cardiovascular disease (ASCVD)-related events; second, to evaluate the relative extent to which neighborhood disadvantage and physiologic risk account for neighborhood-level variation in ASCVD event rates.Observational cohort analysis of geocoded longitudinal electronic health records.A single academic health center and surrounding neighborhoods in northeastern Ohio.109 793 patients from the Cleveland Clinic Health System (CCHS) who had an outpatient lipid panel drawn between 2007 and 2010. The date of the first qualifying lipid panel served as the study baseline.Time from baseline to the first occurrence of a major ASCVD event (myocardial infarction, stroke, or cardiovascular death) within 5 years, modeled as a function of a locally derived neighborhood disadvantage index (NDI) and the predicted 5-year ASCVD event rate from the Pooled Cohort Equations Risk Model (PCERM) of the American College of Cardiology and American Heart Association. Outcome data were censored if no CCHS encounters occurred for 2 consecutive years or when state death data were no longer available (that is, from 2014 onward).The PCERM systematically underpredicted ASCVD event risk among patients from disadvantaged communities. Model discrimination was poorer among these patients (concordance index [C], 0.70 [95% CI, 0.67 to 0.74]) than those from the most affluent communities (C, 0.80 [CI, 0.78 to 0.81]). The NDI alone accounted for 32.0% of census tract-level variation in ASCVD event rates, compared with 10.0% accounted for by the PCERM.Patients from affluent communities were overrepresented. Outcomes of patients who received treatment for cardiovascular disease at Cleveland Clinic were assumed to be independent of whether the patients came from a disadvantaged or an affluent neighborhood.Neighborhood disadvantage may be a powerful regulator of ASCVD event risk. In addition to supplemental risk models and clinical screening criteria, population-based solutions are needed to ameliorate the deleterious effects of neighborhood disadvantage on health outcomes.The Clinical and Translational Science Collaborative of Cleveland and National Institutes of Health.
Preclinical evaluation of TL-1892, a novel orally active taxane with superior in vitro and in vivo efficacy in paclitaxel and docetaxel resistant models
Authors: Robert Abramowitz, Robert Holton, Lewis Metts, Heather Arrington, Michael Edler, Harley Wilcox, Andy Williams, Diego Zorio
Journal: Cancer Research (2008)

723  Paclitaxel and docetaxel have demonstrated parenteral, but not oral, activity in some in vitro and in vivo preclinical tumor models. However, both paclitaxel and docetaxel are not effective in resistant models such as those tumors that over express p-glycoprotein (MDR1). The comparative cytotoxic effects of TL-1892, paclitaxel and docetaxel were tested in a panel of 14 different cell lines using an MTT assay. The cell lines tested included a wide variety of human cancer cell lines: renal: melanoma: ovarian; lung; brain; colon; pancreatic and mesothelioma. TL-1892 was more potent than paclitaxel and docetaxel in all fourteen human cancer cell lines. In the taxane resistant cell lines such as TK10 (renal), OVCAR5 (ovarian), DLD-1 (colon), MSTO-211H (mesothelioma), 786-0 (renal) and A375 (melanoma), TL-1892 was at least 10 times more potent than paclitaxel. These cell lines included MDR1 resistant models and some models with other mechanisms of resistance. The in vivo activity of TL-1892 was tested in athymic nude mice in four different xenograft models. TL-1892 when dosed IV at doses of 30 mg/kg was completely curative in the MX1 human breast cancer model. TL-1892 when dosed IV at doses of 30 mg/kg on an every four day schedule for four doses was completely curative in the A375 human melanoma model. Docetaxel was not effective in this model when dosed on its optimum schedule of every 7 days for three doses. In the taxane resistant MSTO-211H human mesothelioma model, TL-1892 when dosed at 25 mg/kg on an every four day schedule for four doses showed approximately 90% tumor regression. Docetaxel was not effective in this model. In the HT29 human colon model, TL-1892 was dosed orally at a dose of 50 mg/kg and IV at a dose of 25 mg/kg on an every four day schedule for four doses. Both dosing regimens showed similar activity with greater than 90% tumor regression indicating a high bioavailability of TL-1892 when dosed orally. The toxicity of TL-1892 in rats was compared at 12 mg/kg along side docetaxel at the same dose of 12 mg/kg. The docetaxel treated rats showed high amounts of axonal degeneration while the TL-1892 treated animals showed almost no axonal degeneration indicating that TL-1892 may have advantages in the clinic with lessened neurotoxicity compared to paclitaxel and docetaxel. In summary, the oral activity of TL-1892 along with its in vivo and in vitro activity in resistant tumors and its neurotoxicity profile in rats distinguishes it from the clinically useful taxanes, paclitaxel and docetaxel.
Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies
Authors: Olli Dufva, Matti Kankainen, Tiina Kelkka, Shady Adnan Awad, Nodoka Sekiguchi, Bhagwan Yadav, Samuli Eldfors, Heikki Kuusanmäki, Emma I Andersson, Disha Malani, Paavo Pietarinen, Leena Saikko, Panu E Kovanen, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Thomas P. Loughran, Wing Chung Chan, Koichi Ohshima, Tero Aittokallio, Fumihiro Ishida, Satu Mustjoki
Journal: Blood (2016)
Otx2-Genetically Modified Retinal Pigment Epithelial Cells Rescue Photoreceptors after Transplantation
Authors: Christo Kole, Laurence Klipfel, Ying Yang, Vanessa Ferracane, Frederic Blond, Sacha Reichman, Géraldine Millet-Puel, Emmanuelle Clérin, Najate Aït-Ali, Delphine Pagan, Hawa Camara, Marie-Noëlle Delyfer, Emeline F. Nandrot, Jose-Alain Sahel, Olivier Goureau, Thierry Léveillard
Journal: Molecular Therapy (2017)

Inherited retinal degenerations are blinding diseases characterized by the loss of photoreceptors. Their extreme genetic heterogeneity complicates treatment by gene therapy. This has motivated broader strategies for transplantation of healthy retinal pigmented epithelium to protect photoreceptors independently of the gene causing the disease. The limited clinical benefit for visual function reported up to now is mainly due to dedifferentiation of the transplanted cells that undergo an epithelial-mesenchymal transition. We have studied this mechanism in vitro and revealed the role of the homeogene OTX2 in preventing dedifferentiation through the regulation of target genes. We have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells. OTX2 increases significantly the protection of photoreceptors as seen by histological and functional analyses. We observed that the beneficial effect of OTX2 is non-cell autonomous, and it is at least partly mediated by unidentified trophic factors. Transplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.
Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors
Authors: Daniel M. Blumenthal, Dana Goldman, Anupam B. Jena
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Hepatocellular carcinoma complicating hepatitis E virus–related cirrhosis
Authors: Patrick Borentain, Philippe Colson, Emilie Bolon, Philippe Gauchez, Diane Coso, René Gérolami
Journal: Hepatology (2017)

Borentain, Patrick; Colson, Philippe; Bolon, Emilie; Gauchez, Philippe; Coso, Diane; Gérolami, René Author Information
Novel Approach to and Results of Genetic Analysis of 3000 Hemophilia Patients Enrolled in the MyLifeOurFuture Initiative
Authors: Jill Johnsen, Shelley N Fletcher, Haley Huston, Sarah Roberge, Beth K Martin, Martin Kircher, Neil C Josephson, Jay Shendure, Sarah Ruuska, Marion A Koerper, Leslie Meltzer, Glenn F Pierce, Diane Aschman, Barbara Konkle
Journal: Blood (2016)
Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Authors: Ahmed Salem, Marie-Claude Asselin, Bart Reymen, Alan Jackson, Philippe Lambin, Catharine M L West, James P B O’Connor, Corinne Faivre-Finn
Journal: JNCI Journal of the National Cancer Institute (2017)

Oxygen deprivation (hypoxia) in non–small cell lung cancer (NSCLC) is an important factor in treatment resistance and poor survival. Hypoxia is an attractive therapeutic target, particularly in the context of radiotherapy, which is delivered to more than half of NSCLC patients. However, NSCLC hypoxia-targeted therapy trials have not yet translated into patient benefit. Recently, early termination of promising evofosfamide and tarloxotinib bromide studies due to futility highlighted the need for a paradigm shift in our approach to avoid disappointments in future trials. Radiotherapy dose painting strategies based on hypoxia imaging require careful refinement prior to clinical investigation. This review will summarize the role of hypoxia, highlight the potential of hypoxia as a therapeutic target, and outline past and ongoing hypoxia-targeted therapy trials in NSCLC. Evidence supporting radiotherapy dose painting based on hypoxia imaging will be critically appraised. Carefully selected hypoxia biomarkers suitable for integration within future NSCLC hypoxia-targeted therapy trials will be examined. Research gaps will be identified to guide future investigation. Although this review will focus on NSCLC hypoxia, more general discussions (eg, obstacles of hypoxia biomarker research and developing a framework for future hypoxia trials) are applicable to other tumor sites.
線維性骨異形成症におけるPFKFB4媒介の解糖の再プログラムの線維化促進効果【Powered by NICT】
Authors: Lee Mi-Ok, You Chae Hwa, Son Mi-Young, Kim Young-Dae, Jeon Hyejin, Chang Jae-Suk, Cho Yee Sook
Journal: Biomaterials (2016)
Abstract 319: Mirna-125b Reduces Ischemia / Reperfusion (i/r)-induced Apoptosis Through Targeting Multiple Targets in Intrinsic and Extrinsic Apoptosis Pathways
Authors: Peipei Wang, Qiying Chen, Yue Zhou, Arthur M Richards
Journal: Circulation Research (2015)

Apoptosis is mediated through extrinsic and intrinsic pathways, both play a role in ischemia/reperfusion (I/R) injury. Predicted targets for miRNA-125b include extrinsic pathway mediators Traf6 and Tnfrsf1b, and intrinsic mitochondria regulators Bcl-2 family pro-apoptotic effectors Bak1 and BH3-only facilitators Bim, Bmf, Puma. We hypothesized that miRNA-125b directly targets multiple genes to reduce I/R-induced apoptosis. Myoblast H9c2 cells underwent 16 hours 0.2% O 2 hypoxia followed by 2 hours re-oxygenation (H-R, simulating I/R) and were transfected with miRNA-125b mimic vs. scrambled mimic control (25 nmol, miR-125b-M vs. MC) and miR-125b inhibitor vs. inhibitor control (miR-125b-I vs. IC). Cell count/viability, WST assay, cell injury-induced LDH release and apoptotic marker Casp3/7 were measured. Cells were trypsinized for assessment of apoptosis (7-AAD and annexin V double staining) and lysed for RT-qPCR and western blot (WB) analyses. pCMV-Myc-Bak1 plasmids were cloned and transfected into H9c2 for recovery studies. The effects were verified in neonatal rat ventricular myocytes (NRVM). miRNA-125b-M significantly reduced H-R injury as indicated by higher cell count/viability and WST activity, and reduced LDH (miR-125b-M vs. MC p&lt;0.05). qPCR confirmed that (1) miR-125b expression was reduced in H-R; (2) RISC-loaded (immunoprecipitation pull-down Ago-2) miR-125b increased by ~35 fold and reduced to ~3% following mimic and inhibitor transfection respectively; (3) multiple apoptosis-related genes were reduced by miR-125b-M, Bak1, Bmf, Bim, Puma, Traf6 and Tnfrsf1b. All changes were confirmed by WB. Luciferase reporter assays indicated miR-125b bound to the 3’-UTR of all genes tested except Traf6. Total apoptotic cell numbers and Casp3/7 release were significantly reduced by miR-125b-M. The protective effect of miRNA-125b was partially abolished by Bak1 overexpression (pCMV-Myc-Bak1 and miR-125b co-transfection). Protective effects of miRNA-125b were further verified in NRVM. MiRNA-125b inhibitor reversed protective effects and target changes at mRNA and protein level. miR-125b is powerfully cardioprotective in I/R injury due to directly targeting multiple genes in the extrinsic and intrinsic apoptotic pathways.
Anthocyanin-rich berry extracts and epigallocatechin gallate reduce the enhanced invasiveness of estrogen-negative human breast carcinoma cells elicited by serum
Authors: Chantal Barthomeuf, Sylvie Lamy, Richard Beliveau, Philippe Chollet
Journal: Cancer Research (2007)

LB-149  Breast cancer is the second leading cause of cancer-related deaths in North American women. Despite the evidence for a protective effects of fruits and vegetables on breast cancer remains inconclusive, it has been suggested that fruit and vegetable intake might provide protection against estrogen-receptor negative (ER)-negative but not (ER)-positive breast cancer. However, neither the mechanisms leading to this specificity nor the possibility that a polyphenol-rich intake may protect patient with ER--BC against metastasis have been investigated. In the US, the daily intake of anthocyanin in man has beenestimated to be about 200 mg/day. ER_BC cells (ER--BCC) have markedly higher capacity to migrate, invade and proliferate at site of metastasis than ER-positive one’s. The goal of this study was to determine whether anthocyanin-rich extracts (AREs) inhibit the enhanced motility of highly invasive estrogen-receptor-alpha-negative-MDA-MB-231 BCC elicited by the chemotactic agents found in serum Methods: The cell motility was measured in microchemotaxis chambers containing gelatin pre-coated micropore filters (8-mm pore size). After adhesion to the matrix, the cells were treated with the solvent or with epigallocatechin gallate (EGCg), a laboratory-made red grape skin extract (SGE), a highly bioavailable bilberry extract or pilot red grape skin, blackberry, fermented-grape or black currant extracts. The cell migration was initiated by FBS (0.5%) and measured 5 hrs after cell elicitation. Results As expected, serum-stimulation elicited strong MDA-MB-231 cell motility. Although at 25 µg/mL, all tested AREs reduced this chemotactic effect, their respective potency was markedly different. Grape and bilberry AREs provided the highest protection. Both exhibited dose-dependent inhibitory effect. At 25 µg/mL, the most potent one (SGE) decreased the motility of FBS-stimulated MDA-MB-231 cells by up 80% and, was found to be, respectively 3.2- and 2-fold more potent than EGCg and the bilberry extract at similar concentrations. Conclusion. This is the first demonstration that in vitro, anthocyanin-rich berry extracts are able to inhibit the migration and invasiveness of ER--BCC. This suggests that a regular consumption of berries (especially grape and bilberry) might provide protection against the development of primary and secondary ER--breast tumors. New experiences will test this hypothesis in animal model.
Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors.
Authors: Abigail Gifford, Julia Lawrence, Doug Case, Steve Rapp, Laura Baker, Suzanne Craft, David L. Groteluschen, Heidi Klepin, Glenn Lesser, Michelle Joy Naughton, Bonnie Sachs, Thomas A. Samuel, Kaycee Sink, Jeff Williamson, Edward G. Shaw
Journal: Journal of Clinical Oncology (2015)

9560 Background: This abstract uses the National Institute on Aging/Alzheimer’s (NIA/AA) criteria to report the prevalence of MCI in a cohort of breast cancer survivors who received adjuvant chemotherapy. Methods: Wake Forest NCORP Research Base prospective clinical trial 97211 enrolled 62 breast cancer survivors 1-5 year post adjuvant chemotherapy between 7/12-1/13 to test the efficacy of donepezil on cognitive function. Subjective cognitive complaints were evaluated with the Functional Assessment of Cancer Therapy-Cognition. Objective cognitive performance was assessed using standardized/validated neurocognitive measures. Functional status was evaluated with the FACIT-Fatigue. The NIA/AA MCI criteria as applied to this study were: 1) self-reported cognitive complaints (FACT-Cog score < 63), 2) significant cognitive impairment ( ≥ 1.5 SD below the normative mean) in ≥ 1 cognitive domains, 3) preservation of functional independence, and 4) not demented. MCI was further classified as amnestic/non-amnestic and single-/multi-domain. Results: Sixty women between the ages of 39 and 79 completed the objective cognitive battery. At baseline, 80% demonstrated significant cognitive impairment. 58% met the NIA/AA criteria for MCI (of those, 26% were amnestic/multi-domain, 9% amnestic/single-domain, 17% non-amnestic/multi domain, 49% non-amnestic single domain MCI). 22% had significant cognitive impairment with loss of functional independence. Conclusions: In this cohort, 58% met the accepted NIA/AA criteria for MCI. The American Heart and Stroke Associations have adopted these criteria to define Vascular Cognitive Impairment (VCI), vascular MCI (vMCI), and Vascular Dementia (VaD). Similarly, standard criteria to characterize cognitive dysfunction should be applied in the cancer setting. We propose implementing the terms Cancer Cognitive Impairment (CCI), cancer MCI (cMCI), and Cancer Dementia (CaD) to describe the spectrum of cancer- and cancer-treatment associated cognitive impairment.